DNA methylation markers in peripheral blood for psoriatic arthritis. Issue 1 (October 2022)

• Record Type: Journal Article
• Authors: Deng, Min; Su, Yuwen; Wu, Ruifang; Li, Siying; Zhu, Yanshan; Tang, Guishao; Shi, Xiaoli; Zhou, Tian; Zhao, Ming; Lu, Qianjin
• Is Part Of: Journal of dermatological science. Volume 108:Issue 1(2022)
• Page Start: 39
• Page End: 47
• Publication Date: 2022-10
• Subjects: PsA psoriatic arthritis -- PsV psoriasis vulgaris -- HCs healthy controls -- RA rheumatoid arthritis -- LASSO least absolute shrinkage and selector operation -- DMSs differentially methylated sites -- PBMCs peripheral blood mononuclear cells; Psoriasis -- Psoriatic arthritis -- CpG methylation -- Biomarkers; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologie -- Périodiques; 616.5005
• DOI: 10.1016/j.jdermsci.2022.11.001
• Languages: English
• ISSNs: 0923-1811

Abstract

Abstract: Background: The clinical manifestations of psoriatic arthritis (PsA) are highly heterogeneous and no reliable diagnostic biomarkers exist. Objective: We explored the role of DNA methylation CpG markers in the diagnosis of PsA. Methods: DNA methylation array was used to screen for differentially methylated sites (DMSs) in the discovery phase (PsA, n = 25; healthy controls [HCs], n = 19; psoriasis vulgaris [PsV], n = 20). In the validation phase, pyrosequencing was used to identify the DMSs in an expanded cohort (PsA, n = 60; HCs, n = 91; PsV, n = 48; rheumatoid arthritis [RA], n = 60). Logistic regression prediction models were established based on the identified DMSs for the diagnosis of PsA. Results: A total of 17 DMSs differentiating PsA and HCs as well as 11 DMSs differentiating PsA and PsV were screened in the discovery phase. A total of six DMSs (chr14: cg07940072, chr14: 38061320, chr9: cg15734589, chr6: cg12800266, chr3: cg12992827, chr6: cg24500972) differentiating PsA and HCs and two DMSs (chr12: cg16459382, chr2: cg16348668) differentiating PsA and PsV were identified using pyrosequencing. Three logistic regression prediction models were established based on the identified DMSs, which distinguished PsA, RA, PsV, and HCs ( P < 0.001). The models performed well in differentiating PsA from HCs, RA, and PsV (AUC: 0.858, 0.851, and 0.976, respectively). Conclusions: The models based on methylated CpG sites are useful for distinguishing patients with PsA from HCs and those with RA or PsV and are a highly sensitive and specific diagnostic biomarker for PsA. Highlights: DNA methylation markers distinguish psoriatic arthritis from psoriasis vulgaris. DNA methylation plays a crucial role in psoriasis and psoriatic arthritis. DNA methylation serves as a good biomarker for the diagnosis of psoriatic arthritis.